About: Outcome of COVID-19 Patients with Use of Tocilizumab: a single center experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcome of COVID-19 Patients with Use of Tocilizumab: a single center experience Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outcome of COVID-19 Patients with Use of Tocilizumab: a single center experience
Creator	Ali, S Aziz, A Jamil, B
Source	Elsevier
abstract	COVID-19 pandemic has become a global concern. Cytokine release syndrome (CRS) complicates acute respiratory distress syndrome (ARDS) and causes multi-organ failure which can subsequently lead to mortality in COVID-19 patients. Tocilizumab, an interleukin-6 antagonist, has shown to salvage patients with cytokine release storm. In this study, we aim to evaluate therapeutic response of Tocilizumab in COVID-19 patients. A single-arm retrospective review of 40 patients with COVID-19 admitted to The Aga Khan University Hospital from March 2020 to May 2020 was performed. Selection of patients for use of Tocilizumab was based on severity of disease, rapid clinical deterioration, presence of CRS and absence of any absolute contraindication to Tocilizumab. Improvement after Tocilizumab was defined as improvement in oxygen requirement and inflammatory parameters. Serum levels of inflammatory cytokines like C-reactive protein, ferritin, D-dimer and lactate dehydrogenase levels were monitored before and after administering Tocilizumab. Mean age was 62.4 years and 33 (82.5%) were male. 19 (47.5%) patients were critically sick, 18 (45%) were severely sick and 3 (7.5%) were moderately sick. 29 (77.5%) patients showed significant improvement in oxygen requirement, inflammatory parameters and chest x-rays, out of which 28 patients were discharged home. The mean duration between administration of Tocilizumab and overall improvement was 4.3 ± 3.2 days. Hence, Tocilizumab can be used as a possible treatment option in patients with COVID-19 induced CRS but needs monitoring for its adverse effects.
has issue date	2020-08-28(xsd:dateTime)
bibo:doi	10.1016/j.intimp.2020.106926
has license	els-covid
sha1sum (hex)	f6a61f08fcbfd1f7ec71ef8d0ae1ca0347a8b0e1
schema:url	https://doi.org/10.1016/j.intimp.2020.106926
resource representing a document's title	Outcome of COVID-19 Patients with Use of Tocilizumab: a single center experience
resource representing a document's body	covid:f6a61f08fcbfd1f7ec71ef8d0ae1ca0347a8b0e1#body_text
is schema:about of	named entity 'Tocilizumab' named entity 'CRP' named entity 'IL-23' named entity 'CRS' named entity 'mechanical ventilator' named entity 'cough' named entity 'Tocilizumab' named entity 'Pseudomonas' named entity 'treatment modality' named entity 'ARDS' named entity 'Spread of disease' named entity 'LDH' named entity 'lactate dehydrogenase' named entity 'pneumonia' named entity 'connective tissue' named entity 'methylprednisolone' named entity 'Ebola' named entity '5.5' named entity 'CRS' named entity 'MERS' named entity 'respiratory failure' named entity 'chest x-ray' named entity 'candidemia' named entity 'steroids' named entity 'SARS' named entity 'critically ill' named entity 'case series' named entity 'coronavirus' named entity 'phase 2' named entity 'province in China' named entity 'intensive care' named entity 'antiviral therapy' named entity 'critically ill patients' named entity 'respiratory diseases' named entity 'Interleukin 6' named entity 'CD8+' named entity 'CRP' named entity 'ARDS' named entity 'QTc interval' named entity 'SARS-CoV-2' named entity 'randomized controlled trials' named entity 'clinical outcomes' named entity 'HKU1' named entity 'sputum' named entity 'single center' named entity 'comorbidities' named entity 'IL-6' named entity 'organ dysfunction' named entity 'Tocilizumab' named entity 'Karachi' named entity 'OC43' named entity 'respiratory failure' named entity 'COVID-19' named entity 'Tocilizumab' named entity 'clinical trial' named entity 'Tocilizumab' named entity 'anti-viral drugs' named entity 'critically ill patients' named entity 'SARS-CoV' named entity 'critically ill' named entity 'IL-6' named entity 'inflammatory response' named entity 'CRP' named entity 'national treatment' named entity 'comorbidities' named entity 'IL-6' named entity 'China' named entity 'recombinant' named entity 'D-dimer' named entity 'CD4' named entity 'comorbidities' named entity 'ARDS' named entity 'oxygen' named entity 'Tocilizumab' named entity 'LDH' named entity 'Tocilizumab' named entity 'fever' named entity 'antibody' named entity 'organ dysfunction' named entity 'cytotoxic T-cells' named entity 'oxygen' named entity 'Tocilizumab' named entity 'chest x-rays'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software